Deal date
KANDO id: 10433956
Financial Transaction:
Series D
Aderis Pharmaceuticals Inc
Currency
United States Dollar
Value in original currency
45,000,000
Value in USD
45,000,000
Lead investor
| Investor | Country | Notes | |
|---|---|---|---|
|
Paladin Capital GroupPrivate equity firm |
United States | Initial investment. |
Round participants
| Investor | Country | Notes | |
|---|---|---|---|
|
China Development Industrial Bank(CDIB)Private development financial institution in Taiwan. |
Taiwan | Initial investment. |
|
International Biotechnology Trust PLC |
United Kingdom | Initial investment. |
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
MDS Capital Corp |
Canada | Initial investment. |
|
|
NeoMed Management AS |
Norway | Initial investment. |
|
|
Perseus-Soros BioPharmaceutical Fund LP |
United States | Initial investment. |
|
Sanderling Ventures |
United States | Initial investment. |
|
|
Schroder Ventures KK |
Initial investment. | |
|
|
Singapore Bio-Innovations |
Initial investment. | |
|
Temasek Holdings (Pte) LtdSingapore's sovereign wealth fund. |
Singapore | Initial investment. |